CClinicalTrials.gg
Sign In
CompletedNCT00612729Updated Aug 17, 2010

Light Filters in Intraocular Lenses (IOLs) and Its Influence on Colour and Contrast Vision.

A Phase 4 interventional study of Polylens Y30 intraocular lens and Orange Series Model PC 440 Y intraocular lens in Cataract, sponsored by Hospital Hietzing. Completed at 1 site in Austria. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-08-17.

Sponsored by Hospital Hietzing · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
All
01

Study summary

Visible-light-filtering IOLs are implanted increasingly often in cataract surgery. Several studies examined the effect of light-filters on contrast and colour vision. However, the study outcomes were varying. The present study investigated the effect of two light-filtering IOL on colour perception and contrast acuity using highly sensitive measurement methods.

Read the detailed description

Prospective, randomized, double-masked study with intraindividual comparison. Implantation of a Polylens Y30 IOL in one eye and an Orange Series Model PC 440 Y in the contralateral eye.

02

Conditions studied

  • Cataract

Browse trials for

Keywords

  • intraocular lens
  • light filtering intraocular lens
  • contrast acuity
  • color vision
03

In context

Cataract

1,701 studies on the registry are indexed under Cataract; 230 are open to participants now.

This study's enrollment of 32 is below the median of 80 across 1,155 interventional studies indexed under Cataract.

Browse Cataract studies →

Lead sponsor

Hospital Hietzing is the lead sponsor of 15 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • bilateral age-related cataract
  • age 55 to 80 years
  • expected postoperative visual acuity of at least 1.0

Exclusion criteria

Exclusion Criteria:

  • amblyopia
  • corneal scars
  • diabetes
  • arterial hypertonia
  • pseudoexfoliation-syndrome
  • earlier ocular surgeries or laser treatments
  • intraocular tumors
  • color abnormalities
  • expected postoperative visual acuity lower 1.0
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Interventions

  • ProcedurePolylens Y30 intraocular lens

    cataract surgery

  • ProcedureOrange Series Model PC 440 Y intraocular lens

    cataract surgery

06

What researchers measure

Primary outcomes

  1. contrast acuity

    Time frame: 3 month after surgery

Secondary outcomes

  1. visual acuity and color vision

    Time frame: 3 month after surgery

  2. colour perception

    Time frame: 3 month after surgery

07

Study locations

1 site
  • Department of Ophthalmology, Hietzing Hospital
    Vienna, 1130, Austria
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 17, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00612729
Lead sponsor
Hospital Hietzing
First posted
Feb 12, 2008
Start date
May 2008
Primary completion
Nov 2009
Completion
Jun 2010
Last update
Aug 17, 2010

Study contacts

Matthias G Wirtitsch, MD
principal investigator · Dept of Ophthalmology, Hietzing Hospital, Vienna, Austria
Nadja Karnik, MD
study chair · Dept of Ophthalmology, Hietzing Hospital, Vienna, Austria

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Cataract→

Other studies from this sponsor

Hospital Hietzing

Start the discussion